A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
ALX Oncology Inc.
Servier
Novartis
Kumquat Biosciences Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Eli Lilly and Company
IDEAYA Biosciences
BioNTech SE
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Bristol-Myers Squibb
Pheon Therapeutics
AstraZeneca
Eli Lilly and Company
University of Pittsburgh
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
AstraZeneca
Exelixis
Astellas Pharma Inc
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novartis
Kura Oncology, Inc.
Zymeworks BC Inc.
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
AbbVie
Travera Inc
Eli Lilly and Company
Iambic Therapeutics, Inc
7 Hills Pharma, LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Plexium, Inc.
OncoC4, Inc.
Jazz Pharmaceuticals
Genmab